[Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration].

Potential weight gain must be taken into account in the patient's comprehensive treatment approach when initiating antipsychotic treatment with Olanzapine. There are effective preventive and therapeutic pharmacological interventions to control this adverse effect. Not addressing this eventual treatment aspect of Olanzapine treatment may compromise the patient's health and his/her compliance with the pharmacological treatment indicated in serious psychiatric conditions.

Negative outcome after neurosurgery for refractory obsessive-compulsive spectrum disorder.

Objective: The authors sought to determine the long-term outcome of patients with severe and refractory obsessive-compulsive disorder spectrum (OCDS) following neurosurgery.

Method: Five patients who underwent neurosurgery as a last-resort treatment for refractory OCDS were evaluated. On all patients, posttest data was obtained from the Yale-Brown Obsessive-Compulsive Scale, The Overvalued Ideas Scale, the Beck Depression Inventory and the Beck Anxiety Inventory.

[Review and updating of the diagnostic sensibility of the dexamethasone suppression test and urinary determination of phenylethylamine and 3-methoxy-4-hydroxyphenylethylglycol in the diagnosis of endogenous depression].

60 endogenous depressive patients (DSM III: 296.2x, 3x, 296.5x) were studied according to the following diagnostic techniques: DST (Carroll's standardization), Phenyl-ethyl-amine (PEA) urinary quantification (Spatz's technique) and 3-Methoxy-4-Hydroxyphenylethyl Glycol (MHPG) urinary quantification (Bigelow's technique).